Therapy after heart infarct: prevention of reperfusion injury and repair by stem cell transfer
Coordinator: Erhard HOFER
Project Number: 222995
EC contribution: € 2,700,000.00
Project website: http://www.infarctcelltherapy.eu/
A key problem in repair and functional regeneration following myocardial infarction is the inability of heart muscle tissue to regenerate itself and appropriate vascularization under conditions of increased strain caused by the reduced contractibility of the damaged heart. This frequently leads to continuous loss of functional cells, further increase of the infarct area and finally complete loss of heart function. We propose to explore possibilities for cell therapy using different procedures and sources of stem and progenitor cells. First, we will investigate factors stimulatory for stem/progenitor cell release from the bone marrow, their recruitment to the heart and the activation of resident heart stem cells. Second, we will evaluate adoptive transfer of stem/progenitor cells of different sources, from bone marrow, adult and cord blood, adipose tissue and heart tissue itself. The use of ex vivo cultured and differentiated cells including embryonic stem cells will be tested. Third, we will test genetic modification of these cells for improved differentiation, homing and tissue repair. Fourth, we will use a unique artificial scaffold material as a slow release device for factors and as a structural support material for providing the different cell preparations to the damaged areas. This scaffold will aso be used for tissue engineering in vitro followed by insertion of artficial tissue onto the infarct area. This project of high clinical importance is designed to further support the research and development needs of two SMEs, one is determined to become a supplier of growth factor cocktails for clinical stem cell culture, a second is based on the generation and supply of stem cells for clinical use. It will evaluate whether induction of repair by factors, adoptive transfer of stem/progenitor cells or engineered tissue has benefit for heart regeneration and has potential to become a future clinical standard therapy.